Last reviewed · How we verify
CT-P13 SC (Infliximab)
CT-P13 SC (Infliximab) is a TNF-alpha inhibitor; monoclonal antibody Biologic drug developed by Celltrion. It is currently in Phase 3 development for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
CT-P13 SC is a subcutaneous formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation.
CT-P13 SC is a subcutaneous formulation of infliximab, a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | CT-P13 SC (Infliximab) |
|---|---|
| Sponsor | Celltrion |
| Drug class | TNF-alpha inhibitor; monoclonal antibody |
| Target | TNF-alpha (Tumor Necrosis Factor-alpha) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Infliximab is a chimeric monoclonal antibody that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF-alpha signaling, it suppresses the inflammatory cascade underlying autoimmune and inflammatory diseases. CT-P13 is a biosimilar to Remicade (infliximab), and the SC formulation allows for subcutaneous self-administration rather than intravenous infusion.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
- Plaque psoriasis
Common side effects
- Infections (including serious infections)
- Injection site reactions
- Headache
- Upper respiratory tract infections
- Tuberculosis reactivation
- Malignancy risk
Key clinical trials
- Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease (NA)
- A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease
- Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC (PHASE3)
- A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
- CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD) (PHASE3)
- CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC) (PHASE3)
- EFFICACY AND SAFETY OF S.C. INFLIXIMAB IN PATIENTS SWITCHED FROM I.V. FORMULATION OF INFLIXIMAB
- REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-P13 SC (Infliximab) CI brief — competitive landscape report
- CT-P13 SC (Infliximab) updates RSS · CI watch RSS
- Celltrion portfolio CI
Frequently asked questions about CT-P13 SC (Infliximab)
What is CT-P13 SC (Infliximab)?
How does CT-P13 SC (Infliximab) work?
What is CT-P13 SC (Infliximab) used for?
Who makes CT-P13 SC (Infliximab)?
What drug class is CT-P13 SC (Infliximab) in?
What development phase is CT-P13 SC (Infliximab) in?
What are the side effects of CT-P13 SC (Infliximab)?
What does CT-P13 SC (Infliximab) target?
Related
- Drug class: All TNF-alpha inhibitor; monoclonal antibody drugs
- Target: All drugs targeting TNF-alpha (Tumor Necrosis Factor-alpha)
- Manufacturer: Celltrion — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Crohn's disease
- Indication: Drugs for Ulcerative colitis
- Compare: CT-P13 SC (Infliximab) vs similar drugs
- Pricing: CT-P13 SC (Infliximab) cost, discount & access